系统性糖皮质激素在鼻窦疾病管理中的应用:循证专家综述
该综述检索2013至2023年MEDLINE、EMBASE和Cochrane数据库,按慢性鼻窦炎伴或不伴鼻息肉分组评估系统性糖皮质激素(SCS)证据。短期SCS可短期改善鼻息肉大小、鼻塞和嗅觉,但获益数周内消退;常规术后SCS无支持证据;CRSsNP证据有限,反复使用累积毒性。
要点
- 短期SCS可短期改善CRSwNP鼻息肉大小、鼻塞和嗅觉,但需后续鼻用激素维持。
- 术前SCS改善术中视野,但存在 comparable 非激素技术;常规术后SCS无优势。
- CRSsNP证据有限,仅早期或选择性药物治疗者可能获益;反复使用累积毒性。
核心结论
- SCS在慢性鼻窦炎中作用窄且时限短,应强调优化局部治疗、合适手术和生物制剂以减少全身激素暴露。
研究设计与样本
- 循证综述检索MEDLINE、EMBASE和Cochrane数据库2013至2023年文献,按CRSwNP和CRSsNP分组并依证据质量和获益-伤害平衡分级推荐。
主要发现
- CRSwNP中短期SCS一致短期改善鼻息肉大小、鼻塞和嗅觉功能,但数周内获益消退除非后续鼻用激素。
- 术前SCS改善术中视野,但存在 comparable 非激素技术;常规术后SCS无支持,不优于局部治疗。
- 共病亚组未见额外获益;CRSsNP证据有限,仅早期疾病或选择性药物治疗病例可能获益。
- 反复使用SCS导致累积毒性。
临床怎么用
- CRSwNP可短期使用SCS改善息肉、鼻塞和嗅觉,但应后续鼻用激素并避免常规术后使用。
- 优先优化局部治疗、合适鼻窦手术和生物制剂,以最小化全身激素暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti-inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications. Despite widespread use, evidence-based guidance on optimal indications, timing, and duration of SCS in CRS remains inconsistent. METHODOLOGY/PRINCIPAL: An evidence-based review was performed using MEDLINE, EMBASE, and Cochrane databases (2013-2023). Studies were screened and categorized into two primary groups: CRS with (CRSwNP) or without (CRSsNP) nasal polyps. Within CRSwNP, evidence was subcategorized by indication, including (1) polyp size reduction, (2) olfactory dysfunction, (3) comorbid disease, and (4) perioperative use, encompassing pre- and postoperative SCS administration. The CRSsNP category included studies evaluating SCS in non-polypoid disease, with or without comorbidities. Recommendations were graded according to evidence quality and the balance of benefit versus harm. RESULTS: Short courses of SCS provide consistent, short-term improvements in nasal polyp size, nasal congestion, and olfactory function in CRSwNP, but benefits wane within weeks unless followed by intranasal corticosteroids. Preoperative SCS improves intraoperative visualization, though comparable nonsteroidal techniques exist. Routine postoperative SCS are not supported, showing no meaningful advantage over topical therapy. No additional benefit was seen in comorbid subgroups. Evidence in CRSsNP is limited, with possible benefit only in early disease or select medically managed cases. Repeated use contributes to cumulative toxicity. CONCLUSIONS: SCS have a narrow, time-limited role in CRS. Stewardship should emphasize optimized topical therapy, appropriate sinus surgery, and biologics to minimize systemic steroid exposure.
引用
- Thamboo A, Gigliotti D, De Corso E, et al. Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence-Based Expert Review. Int Forum Allergy Rhinol. 2026. PMID: 42411021. doi:10.1002/alr.70211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。